RxDoctor Payments Data

Tiffany Tran, NP

Psychiatric/Mental Health · Anaheim, CANPI 1922770551

Payments from drug & device makers

$8,900in general payments, 2019–2025

Across 431 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Johnson & Johnson$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$622
  • Otsuka America Pharmaceutical, Inc.$568
  • Alkermes, Inc.$544
  • plus $3K from 20 others

What the payments were for

  • Food & beverage$8,83999%
  • Education$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,900 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$10,577
Medicare patients
26
Services billed
152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl12$17,218
Duloxetine Hcl36$2,470
Aripiprazole29$1,312
Trazodone Hcl45$1,001
Bupropion XlBupropion Hcl59$854
Quetiapine Fumarate41$691
Hydroxyzine Pamoate15$536
Buspirone Hcl55$470
Gabapentin45$424
Vilazodone Hcl13$353
Olanzapine29$343
Venlafaxine Hcl ErVenlafaxine Hcl36$292
Hydroxyzine Hcl18$292
Propranolol Hcl20$174
Mirtazapine24$168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,970$17,21812 claims
Almatica Pharma LLCSertraline Hcl$140$13436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →